AOA Dx focuses on early-stage cancer detection within the healthcare industry. It provides diagnostic solutions that use artificial intelligence and proprietary biomarker technology to identify cancer at an early stage. Its main offering includes the GlycoLocate platform, which employs a multi-omics approach to analyse tumour markers for cancer diagnostics, and the liquid biopsy test, which is used for the detection of ovarian cancer.